Cargando…
COVID-19 Convalescent Plasma and Clinical Trials: Understanding Conflicting Outcomes
Convalescent plasma (CP) recurs as a frontline treatment in epidemics because it is available as soon as there are survivors. The COVID-19 pandemic represented the first large-scale opportunity to shed light on the mechanisms of action, safety, and efficacy of CP using modern evidence-based medicine...
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
American Society for Microbiology
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9491201/ https://www.ncbi.nlm.nih.gov/pubmed/35262370 http://dx.doi.org/10.1128/cmr.00200-21 |